Breaking News, Collaborations & Alliances

Valeant GSK Complete Retigabine Collaboration

Valeant Pharmaceuticals International has concluded its exclusive worldwide collaboration agreement with GlaxoSmithKline for retigabine, an investigational drug for the treatment of adult epilepsy patients with refractory partial onset seizures. Under the terms of the agreement, Valeant received an upfront payment of $125 million from GSK.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters